Who
Mark A. Velleca
President & CEO
Company insider
Files Form 4 as: President & CEO, Black Diamond Therapeutics; President and CEO, G1 Therapeutics.
In numbers
- Trades disclosed
- 160
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $8.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Dec 2017
- Last trade
- 21 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jan 2026filed 23 Jan 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 30 Jan 2025filed 31 Jan 2025 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 30 Jan 2025filed 31 Jan 2025 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 14 Feb 2024filed 15 Feb 2024 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —537,000 at $0.00 | filing |
| 17 Sep 2023filed 18 Sep 2023 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 15 Sep 2023filed 18 Sep 2023 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | $19K5,208 at $3.60 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code M | —57,286 at $0.00 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code M | —2,714 at $0.00 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeutics | SEC FORM 4 Code M | $22K57,286 at $0.39 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeutics | SEC FORM 4 Sold | $115K57,286 at $2.00 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeutics | SEC FORM 4 Code M | $8142,714 at $0.30 | filing |
| 8 Aug 2023filed 10 Aug 2023 | G1 Therapeutics | SEC FORM 4 Sold | $5,4822,714 at $2.02 | filing |
| 16 Jun 2023filed 16 Jun 2023 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | $19K8,929 at $2.10 | filing |
| 16 May 2023filed 17 May 2023 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 16 Mar 2023filed 20 Mar 2023 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | $19K11,228 at $1.67 | filing |
| 16 Dec 2022filed 19 Dec 2022 | BDTX Black Diamond TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K8,424 at $1.50 | filing |
| 18 Oct 2022filed 20 Oct 2022 | G1 Therapeuticsoption or derivative | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 18 Oct 2022filed 20 Oct 2022 | G1 Therapeutics | SEC FORM 4 Code M | $5,85015,000 at $0.39 | filing |
| 18 Oct 2022filed 20 Oct 2022 | G1 Therapeutics | SEC FORM 4 Sold | $176K15,000 at $11.70 | filing |
News
No headline names them, or the companies they trade most, lately.